Jensen I M
University Department of Haematology and Medicine, Arhus Amtssygehus, Denmark.
Leuk Lymphoma. 1995 Dec;20(1-2):17-25. doi: 10.3109/10428199509054749.
Evaluating the proliferative activity of the immature erythro- and myelopoiesis as well as the mature myelopoiesis in 21 MDS patients and 14 healthy controls by simultaneously staining bone marrow cells for surface phenotype and DNA content, we found the percentages of proliferating S-phase cells in the early stage of MDS were higher. With disease progression evaluated by the FAB classification this parameter decreased significantly for both the immature myelo- and erythropoiesis. Evaluation of the proliferative activity of the mature myelopoiesis defined by the CD66 antigen revealed no difference between the normal controls and the MDS patients. Using another assay simultaneously labelling bone marrow cells for three leucocyte differentiation antigens during treatment with GM-CSF and low-dose AraC the cells clearly differentiated in one case. In another patient the disease seemed to progress as evaluated by cells only expressing immature antigens. The above mentioned immunophenotypic changes persisted at least one month after termination of treatment. In conclusion, the evaluation of proliferation and differentiation of leucocyte subsets using multiparameter flowcytometric assays in myelodysplastic patients from different FAB groups before as well as during treatment with haemopoietic growth factors may prove valuable in the future.
通过同时对骨髓细胞进行表面表型和DNA含量染色，评估21例骨髓增生异常综合征（MDS）患者和14名健康对照者中未成熟红细胞生成、髓细胞生成以及成熟髓细胞生成的增殖活性，我们发现MDS早期增殖S期细胞的百分比更高。随着通过FAB分类评估的疾病进展，未成熟髓细胞生成和红细胞生成的这一参数均显著下降。通过CD66抗原定义的成熟髓细胞生成的增殖活性评估显示，正常对照者与MDS患者之间无差异。在使用粒细胞-巨噬细胞集落刺激因子（GM-CSF）和小剂量阿糖胞苷（AraC）治疗期间，采用另一种检测方法同时对骨髓细胞进行三种白细胞分化抗原标记，在1例患者中细胞明显分化。在另1例患者中，仅表达未成熟抗原的细胞提示疾病似乎进展。上述免疫表型变化在治疗终止后至少持续1个月。总之，在不同FAB组的骨髓增生异常患者治疗前以及造血生长因子治疗期间，使用多参数流式细胞术检测评估白细胞亚群的增殖和分化，未来可能被证明是有价值的。
